Daxor corporation awarded grant from the center for advancing point of care technologies (capcat) to develop a point-of-care blood volume analyzer

New york, feb. 05, 2021 (globe newswire) -- daxor corporation (nyse mkt: dxr), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the center for advancing point of care technologies (capcat), a program run by the massachusetts medical device development center (m2d2) funded by the national heart, lung, and blood institute and the national center for complementary and integrative health, both part of the national institutes of health (nih), to develop a smart, point-of-care heart failure diagnostic for quantification of intravascular fluid overload to enable precision diuretic dosing.
DXR Ratings Summary
DXR Quant Ranking